Susquehanna International Group’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-55,700
| Closed | -$91.3K | – | 12462 |
|
|
2025
Q3 | $91.3K | Buy |
+55,700
| New | +$62K | ﹤0.01% | 11620 |
|
|
2025
Q2 | – | Sell |
-29,400
| Closed | -$23.8K | – | 12743 |
|
|
2025
Q1 | $23.8K | Sell |
29,400
-856,500
| -97% | -$986K | ﹤0.01% | 12071 |
|
|
2024
Q4 | $1.22M | Buy |
+885,900
| New | +$994K | ﹤0.01% | 6470 |
|
|
2024
Q3 | – | Sell |
-29,600
| Closed | -$51.2K | – | 12082 |
|
|
2024
Q2 | $51.2K | Sell |
29,600
-38,800
| -57% | -$78.1K | ﹤0.01% | 11403 |
|
|
2024
Q1 | $163K | Buy |
68,400
+48,500
| +244% | +$119K | ﹤0.01% | 10821 |
|
|
2023
Q4 | $66.3K | Sell |
19,900
-95,800
| -83% | -$257K | ﹤0.01% | 11582 |
|
|
2023
Q3 | $433K | Buy |
115,700
+82,700
| +251% | +$382K | ﹤0.01% | 8571 |
|
|
2023
Q2 | $141K | Buy |
+33,000
| New | +$195K | ﹤0.01% | 10637 |
|
|
2023
Q1 | – | Sell |
-35,000
| Closed | -$277K | – | 12638 |
|
|
2022
Q4 | $277K | Buy |
+35,000
| New | +$269K | ﹤0.01% | 9286 |
|
|
2022
Q1 | – | Sell |
-10,300
| Closed | -$164K | – | 13056 |
|
|
2021
Q4 | $164K | Sell |
10,300
-6,300
| -38% | -$110K | ﹤0.01% | 11683 |
|
|
2021
Q3 | $267K | Buy |
+16,600
| New | +$243K | ﹤0.01% | 10852 |
|
|
2021
Q1 | – | Sell |
-20,600
| Closed | -$358K | – | 12279 |
|
|
2020
Q4 | $358K | Sell |
20,600
-4,700
| -19% | -$83.7K | ﹤0.01% | 8928 |
|
|
2020
Q3 | $464K | Sell |
25,300
-1,800
| -7% | -$33.5K | ﹤0.01% | 7842 |
|
|
2020
Q2 | $484K | Sell |
27,100
-41,000
| -60% | -$694K | ﹤0.01% | 7432 |
|
|
2020
Q1 | $1.1M | Sell |
68,100
-23,400
| -26% | -$432K | ﹤0.01% | 5163 |
|
|
2019
Q4 | $1.65M | Sell |
91,500
-14,200
| -13% | -$262K | ﹤0.01% | 4642 |
|
|
2019
Q3 | $2.14M | Buy |
105,700
+63,600
| +151% | +$1.27M | ﹤0.01% | 4045 |
|
|
2019
Q2 | $930K | Buy |
42,100
+23,600
| +128% | +$410K | ﹤0.01% | 5828 |
|
|
2019
Q1 | $252K | Buy |
+18,500
| New | +$247K | ﹤0.01% | 7522 |
|
|
2018
Q4 | – | Sell |
-188,300
| Closed | -$3.11M | – | 9013 |
|
|
2018
Q3 | $3.11M | Buy |
188,300
+50,000
| +36% | +$886K | ﹤0.01% | 3314 |
|
|
2018
Q2 | $1.94M | Buy |
+138,300
| New | +$1.98M | ﹤0.01% | 4066 |
|
|
2017
Q4 | – | Sell |
-40,300
| Closed | -$538K | – | 9281 |
|
|
2017
Q3 | $538K | Buy |
40,300
+18,000
| +81% | +$238K | ﹤0.01% | 6389 |
|
|
2017
Q2 | $320K | Buy |
22,300
+600
| +3% | +$11.5K | ﹤0.01% | 7462 |
|
|
2017
Q1 | $459K | Buy |
21,700
+13,300
| +158% | +$327K | ﹤0.01% | 6641 |
|
|
2016
Q4 | $236K | Sell |
8,400
-3,400
| -29% | -$95.1K | ﹤0.01% | 8391 |
|
|
2016
Q3 | $316K | Buy |
+11,800
| New | +$322K | ﹤0.01% | 6842 |
|
Other funds holding CHRS
VCM
SB
KKRC
CM
CWG
Susquehanna International Group's CHRS Position: Q1 2026 in Review
Susquehanna International Group reduced its Coherus Oncology (CHRS) stake by 25% in Q1 2026, selling an estimated $168K and leaving 287,500 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #9750.
Susquehanna International Group first reported a position in CHRS in Q4 2014 and has held it in 33 quarters since. The position peaked at $2.83M in Q2 2023. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.
- Susquehanna International Group held 287,500 shares of Coherus Oncology worth $486K as of Q1 2026.
- Susquehanna International Group sold 94,741 Coherus Oncology shares in Q1 2026, an estimated $168K.
- Coherus Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9750 holding.
- Susquehanna International Group first reported a position in Coherus Oncology in Q4 2014 and has held it in 33 quarters since.
- Susquehanna International Group's Coherus Oncology position peaked at $2.83M in Q2 2023.
- 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.